Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Recommendation of “Moderate Buy” by Brokerages

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has received an average recommendation of “Moderate Buy” from the eighteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $54.25.

Several research firms have recently commented on TNDM. Canaccord Genuity Group reduced their price target on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Piper Sandler restated an “overweight” rating and issued a $55.00 target price (up previously from $50.00) on shares of Tandem Diabetes Care in a research report on Friday, August 2nd. Barclays upped their price target on Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Robert W. Baird cut their price objective on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research report on Thursday, November 7th. Finally, UBS Group raised shares of Tandem Diabetes Care to a “hold” rating in a research report on Friday, August 2nd.

Tandem Diabetes Care Stock Down 4.4 %

Shares of NASDAQ:TNDM opened at $27.34 on Tuesday. Tandem Diabetes Care has a 52-week low of $17.33 and a 52-week high of $53.69. The stock has a market cap of $1.80 billion, a P/E ratio of -14.17 and a beta of 1.36. The business has a fifty day moving average of $37.46 and a two-hundred day moving average of $41.64. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm had revenue of $243.97 million during the quarter, compared to analyst estimates of $224.14 million. During the same quarter in the prior year, the firm posted ($0.38) earnings per share. Tandem Diabetes Care’s quarterly revenue was up 31.4% on a year-over-year basis. On average, research analysts expect that Tandem Diabetes Care will post -1.73 earnings per share for the current year.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of hedge funds have recently bought and sold shares of TNDM. Brooklyn Investment Group purchased a new stake in shares of Tandem Diabetes Care during the third quarter worth approximately $28,000. Assetmark Inc. acquired a new position in Tandem Diabetes Care during the 3rd quarter worth approximately $29,000. ORG Wealth Partners LLC purchased a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $30,000. ORG Partners LLC acquired a new stake in shares of Tandem Diabetes Care in the 2nd quarter valued at $31,000. Finally, Headlands Technologies LLC purchased a new stake in shares of Tandem Diabetes Care during the 1st quarter worth $35,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.